About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT06535997

Descriptive Cohort of French Patients Treated With Carbonetherapy Since October 2010 Outside PHRC-ETOILE

Since the 1990s, carbonetherapy radiotherapy has been developed in a few sites around the world, mainly to treat inoperable and highly radioresistant tumors. In the absence of a treatment center of th...

Lead sponsor: Hospices Civils de Lyon•2 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Hospices Civils de Lyon

Collaborators

Centre François Baclesse, Centre de lutte contre le cancer (CLCC)

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Patients aged ≥ 18 years at the time of inclusion
•* Unresectable or non-operable cancers, or those with macroscopically incomplete resection (R2)
•* Radiation-resistant cancers considered eligible according to the following indicative list:
•* Cystic adenoid carcinomas (CAK) of the head and neck (excluding laryngeal and tracheal localizations)
•* Soft-tissue sarcomas
•* Pleiomorphic rhabdomyosarcomas only
•* Retroperitoneal sarcomas subject to technical feasibilitý - movement)
•* Osteosarcomas of any location and any grade
•* Chondrosarcomas (skull base excluded) grade greater than 2
•* Chordomas of the axial skeleton and pelvis (excluding skull base)
•* Angiosarcomas
•Patients who have not objected to the re-use of medical data for cancer research purposes, and who agree to be contacted by the investigator to complete the quality of life and care pathway questionnaires.

Exclusion Criteria

•Refusal by the living patient to participate in research
•Failure to carry out initially planned carbon therapy treatment

Related studies

RECRUITINGPhase 3

A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)

NCT06312137 · Non Small Cell Lung Cancer

RECRUITINGPhase 3

Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract Cancer

NCT06467357 · Biliary Tract Cancer

HER2-PET: Predicting T-DXd Efficacy and HER2 Heterogeneity

NCT07586215 · Breast Cancer Metastatic

RECRUITINGPhase 3

A Study Comparing Tarlatamab, Durvalumab, Carboplatin, and Etoposide Versus Durvalumab, Carboplatin, and Etoposide in First-line Extensive Stage Small-Cell Lung Cancer (ES-SCLC)

NCT07005128 · Small-cell Lung Cancer, Extensive Stage Small-cell Lung Cancer

RECRUITINGPhase 1/2

A Phase Ib/Ⅱ Clinical Trial of LBL-024 Combined With Paclitaxel in Patients With Platinum-resistant Ovarian Cancer

NCT07042802 · Ovarian Cancer

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: August 6, 2025Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment62

Start dateMay 2025

Last updatedAug 6, 2025

Condition

Cancer Cystic Carcinomas, Adenoid Soft-tissue Sarcomas Rhabdomyosarcoma Pleomorphic Sarcoma,Soft Tissue+4 more

Locations shown

Centre François Baclesse, Centre de lutte contre le cancer (CLCC)

Caen

Hôpital Michallon, CHU de Grenoble-Alpes

Grenoble

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: August 6, 2025Data synced to Clareo: May 25, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions